Advertisement

Chronic Allograft Nephropathy

      Summary

      Chronic allograft nephropathy (CAN) remains the Achilles heel of renal transplantation. In spite of the significant strides achieved in one-year renal allograft survival with newer immunosuppressant strategies, the fate of long-term renal allograft survival remains unchanged. The number of renal transplant recipients returning to dialysis has doubled in the past decade. This is especially important since these patients pose a significantly increased likelihood of dying while on the waiting list for retransplantation, due to increasing disparity between donor organ availability versus demand and longer waiting time secondary to heightened immunologic sensitization from their prior transplants. In this review we analyze the latest literature in detail and discuss the definition, natural history, pathophysiology, alloantigen dependent and independent factors that play a crucial role in CAN and the potential newer therapeutic targets on the horizon. This article highlights the importance of early identification and careful management of all the potential contributing factors with particular emphasis on prevention rather than cure of CAN as the core management strategy.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Seminars in Nephrology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • U.S. Renal Data System
        USRDS 2004 annual report: atlas of end-stage renal disease in the United States. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD2004
        • Meier-Kriesche H.U.
        • Schold J.D.
        • Kaplan B.
        Long-term renal allograft survival: have we made significant progress or is it time to rethink our analytic and therapeutic strategies?.
        Am J Transplant. 2004; 4: 1289-1295
        • Cohen D.J.
        • St Martin L.
        • Christensen L.L.
        • Bloom R.D.
        • Sung R.S.
        Kidney and pancreas transplantation in the United States, 1995-2004.
        Am J Transplant. 2006; 6: 1153-1169
        • Chapman J.R.
        • O’Connell P.J.
        • Nankivell B.J.
        Chronic renal allograft dysfunction.
        J Am Soc Nephrol. 2005; 16: 3015-3026
        • Racusen L.C.
        • Solez K.
        • Colvin R.B.
        • et al.
        The Banff 97 working classification of renal allograft pathology.
        Kidney Int. 1999; 55: 713
        • Solez K.
        • Axelsen R.A.
        • Benediktsson H.
        • et al.
        International standardization of criteria for the histologic diagnosis of renal allograft rejection: the Banff working classification of kidney transplant pathology.
        Kidney Int. 1993; 44: 411
        • Ivanyi B.
        Transplant capillaropathy and transplant glomerulopathy: ultrastructural markers of chronic renal allograft rejection.
        Nephrol Dial Transplant. 2003; 18: 655-660
        • Solez K.
        • VIncenti F.
        • Filo R.
        Histopathological findings from 2-year protocol biopsies from a US multicenter kidney transplant trial comparing tacrolimus versus cyclosporine: a report of the FK506 kidney transplant study group.
        Transplantation. 1998; 66: 1736-1740
        • Glassock R.J.
        • Feldman D.
        • Reynolds E.S.
        • Dammin G.J.
        • Merrill J.P.
        Human renal isografts: a clinical and pathologic analysis.
        Medicine. 1968; 47 (Baltimore): 411-454
        • Tullius S.G.
        • Tilney N.L.
        Both allo-antigen dependent and independent factors influence chronic allograft rejection.
        Transplantation. 1995; 59: 313-318
        • Sayegh M.H.
        • Carpenter M.H.
        Role of indirect allorecognition in allograft rejection.
        Int Rev Immunol. 1996; 13: 221-229
        • Vella J.P.
        • Spadafora-Ferreira M.
        • Murphy B.
        • Alexander S.I.
        • Harmon W.
        • Carpenter C.B.
        • Sayegh M.H.
        Indirect allorecognition of major histocompatibility complex allopeptides in human renal transplant recipients with chronic graft dysfunction.
        Transplantation. 1997; 64: 795-800
        • Ciubotariu R.
        • Liu Z.
        • Colovai A.I.
        • Ho E.
        • Itescu S.
        • Ravalli S.
        • Hardy M.A.
        • Cortesini R.
        • Rose E.A.
        • Suciu-Foca N.
        Persistent allopeptide reactivity and epitope spreading in chronic rejection of organ allografts.
        J Clin Invest. 1998; 101: 398-405
        • Rothstein D.M.
        • Sayegh M.H.
        T-cell costimulatory pathways in allograft rejection and tolerance.
        Immunol Rev. 2003; 196: 85-108
        • Khoury S.J.
        • Sayegh M.H.
        The roles of the new negative T cell costimulatory pathways in regulating autoimmunity.
        Immunity. 2004; 20: 529-538
        • Adams A.B.
        • Shirasugi N.
        • Jones T.R.
        • Durham M.M.
        • Strobert E.A.
        • Cowan S.
        • Rees P.
        • Hendrix R.
        • Price K.
        • Kenyon N.S.
        • Hagerty D.
        • Townsend R.
        • Hollenbaugh D.
        • Pearson T.C.
        • Larsen C.P.
        Development of a chimeric anti-CD40 monoclonal antibody that synergizes with LEA29Y to prolong islet allograft survival.
        J Immunol. 2005; 174: 542-550
        • Kirk A.D.
        • Harlan D.M.
        • Armstrong N.N.
        • Davis T.A.
        • Dong Y.
        • Gray G.S.
        • Hong X.
        • Thomas D.
        • Fechner Jr, J.H.
        • Knechtle S.J.
        CTLA4-Ig and anti-CD40 ligand prevent renal allograft rejection in primates.
        Proc Natl Acad Sci U S A. 1997; 94: 8789-8794
        • Vincenti F.
        New monoclonal antibodies in renal transplantation.
        Minerva Urol Nefrol. 2003; 55: 57-66
        • Vincenti F.
        • Larsen C.
        • Durrbach A.
        • Wekerle T.
        • Nashan B.
        • Blancho G.
        • Lang P.
        • Grinyo J.
        • Halloran P.F.
        • Solez K.
        • Hagerty D.
        • Levy E.
        • Zhou W.
        • Natarajan K.
        • Charpentier B.
        Belatacept Study Group Costimulation blockade with belatacept in renal transplantation.
        N Engl J Med. 2005; 353: 770-781
        • Russell P.
        • Chase C.
        • Winn H.
        • et al.
        Coronary atherosclerosis in transplanted mouse hearts.
        J Immunol. 1994; 152: 5135-5141
        • Regele H.
        • Bohmig G.A.
        • Habicht A.
        • et al.
        Capillary deposition of complement split product C4d in renal allografts is associated with basement membrane injury in peritubular and glomerular capillaries.
        J Am Soc Nephrol. 2002; 13: 2371-2380
        • Mauiyyedi S.
        • Pelle P.D.
        • Saidman S.
        • et al.
        Chronic humoral rejection: identification of antibody-mediated chronic renal allograft rejection by C4d deposits in peritubular capillaries.
        J Am Soc Nephrol. 2001; 12: 574-582
        • Pelletier R.P.
        • Hennessy P.K.
        • Adams P.W.
        • et al.
        Clinical significance of MHC-reactive alloantibodies that develop after kidney or kidney-pancreas transplantation.
        Am J Transplant. 2002; 2: 134-141
        • Tinckam K.J.
        • Chandraker A.
        Mechanisms and role of HLA and non-HLA alloantibodies.
        Clin J Am Soc Nephrol. 2006; 1: 404-414
        • Terasaki P.I.
        • Ozawa M.
        Predictive value of HLA antibodies and serum creatinine in chronic rejection: results of a 2-year prospective trial.
        Transplantation. 2005; 80: 1194-1197
        • van Saase J.L.
        • van der Woude F.J.
        • Thorogood J.
        • Hollander A.A.
        • van Es L.A.
        • Weening J.J.
        • van Bockel J.H.
        • Bruijn J.A.
        The relation between acute vascular and interstitial renal allograft rejection and subsequent chronic rejection.
        Transplantation. 1995; 59: 1280-1285
        • Sijpkens Y.W.
        • Doxiadis I.I.
        • De Fijter J.W.
        • Mallat M.J.
        • van Es L.A.
        • De Lange P.
        • Zwinderman A.H.
        • Westendorp R.G.
        • van Kemenade F.J.
        • Bruijn J.A.
        • Claas F.H.
        • Paul L.C.
        Sharing cross-reactive groups of MHC class I improves long-term graft survival.
        Kidney Int. 1999; 56: 1920-1927
        • Humar A.
        • Kerr S.
        • Gillingham K.J.
        • Matas A.J.
        Features of acute rejection that increase risk for chronic rejection.
        Transplantation. 1999; 68: 1200-1203
        • Humar A.
        • Payne W.D.
        • Sutherland D.E.
        • Matas A.J.
        Clinical determinants of multiple acute rejection episodes in kidney transplant recipients.
        Transplantation. 2000; 69: 2357-2360
        • Joseph J.T.
        • Kingsmore D.B.
        • Junor B.J.
        • Briggs J.D.
        • Mun Woo Y.
        • Jaques B.C.
        • Hamilton D.N.
        • Jardine A.G.
        • Jindal R.M.
        The impact of late acute rejection after cadaveric kidney transplantation.
        Clin Transplant. 2001; 15: 221-227
        • Meier-Kriesche H.U.
        • Schold J.D.
        • Srinivas T.R.
        • Kaplan B.
        Lack of improvement in renal allograft survival despite a marked decrease in acute rejection rates over the most recent era.
        Am J Transplant. 2004; 4: 378-383
        • Matas A.J.
        • Gillingham K.J.
        • Payne W.D.
        • Najarian J.S.
        The impact of an acute rejection episode on long-term renal allograft survival (t1/2).
        Transplantation. 1994; 57: 857-859
        • Kaplan B.
        Overcoming barriers to long-term graft survival.
        Am J Kidney Dis. 2006; 47: S52-S64
        • Hata Y.
        • Cecka J.M.
        • Takemoto S.
        • et al.
        Effects of changes in the criteria for nationally shared kidney transplants for HLA-matched patients.
        Transplantation. 1998; 65: 208-212
        • Morris P.J.
        • Johnson R.J.
        • Fuggle S.V.
        • et al.
        • HLA Task Force of the Kidney Advisory Group of the United Kingdom Transplant Support Service Authority (UKTSSA)
        Analysis of factors that affect outcome of primary cadaveric renal transplantation in the UK.
        Lancet. 1999; 354: 1147-1152
        • Opelz G.
        New immunosuppressions and HLA matching.
        Transplant Proc. 2001; 33: 467-468
        • Pirsch J.D.
        • D’Alessandro A.M.
        • Sollinger H.W.
        • Hoffmann R.M.
        • Roecker E.
        • Voss B.J.
        • Lorentzen D.
        • Knechtle S.J.
        • Reed A.
        • Kalayoglu M.
        • et al.
        The effect of donor age, recipient age, and HLA match on immunologic graft survival in cadaver renal transplant recipients.
        Transplantation. 1992; 53: 55-59
        • Takemoto S.
        • Port F.K.
        • Claas F.H.
        • Duquesnoy R.J.
        HLA matching for kidney transplantation.
        Hum Immunol. 2004; 65: 1489-1505
        • Sijpkens Y.W.
        • Doxiadis I.I.
        • De Fijter J.W.
        Sharing cross-reactive groups of MHC class I improves long-term graft survival.
        Kidney Int. 1999; 10: 2237-2243
        • Sijpkens Y.W.
        • Doxiadis I.I.
        • Mallat M.J.
        • et al.
        Early versus late acute rejection episodes in renal transplantation.
        Transplantation. 2003; 75: 204-220
        • Takemoto S.K.
        • Cho Y.W.
        • Gjertson D.W.
        Transplant risks.
        in: Terasaki P.I. Cecka J.M. Clinical transplants 1999. Tissue Typing Laboratory, Los Angeles1999: 325
        • Goldfarb-Rumyantzev A.
        • Hurdle J.F.
        • Scandling J.
        • et al.
        Duration of end-stage renal disease and kidney transplant outcome.
        Nephrol Dial Transplant. 2005; 20: 167-175
        • Neylan J.F.
        • Sayegh M.H.
        • Coffman T.M.
        • et al.
        • ASN Transplant Advisory Group
        • American Society of Nephrology
        The allocation of cadaver kidneys for transplantation in the United States: consensus and controversy.
        J Am Soc Nephrol. 1999; 10: 2237-2243
        • Guttmann R.D.
        Cadaver kidneys: the rules of rationing.
        Lancet. 1996; 348: 456-457
        • Helderman J.H.
        • Goral S.
        The allocation of cadaveric kidneys.
        N Engl J Med. 1999; 341: 1468-1469
        • Opelz G.
        Non-HLA transplantation immunity revealed by lymphocytotoxic antibodies.
        Lancet. 2005; 365: 1570-1576
        • Martin L.
        • Guignier F.
        • Mousson C.
        • et al.
        Detection of donor specific anti HLA antibodies with flow cytometry in eluates and sera from renal transplant recipients with chronic allograft nephropathy.
        Transplantation. 2003; 76: 395-400
        • Beimler J.H.
        • Susal C.
        • Zeier M.
        Desensitization strategies enabling successful renal transplantation in highly sensitized patients.
        Clin Transplant. 2006; 20: 7-12
        • Almond P.
        • Matas A.
        • Gillingham K.
        • et al.
        Risk factors for chronic rejection in renal allograft recipients.
        Transplantation. 1993; 55: 752-756
        • Ratcliffe P.J.
        • Dudley C.R.
        • Higgins R.M.
        • et al.
        Randomised controlled trial of steroid withdrawal in renal transplant recipients receiving triple immunosuppression.
        Lancet. 1996; 348: 643-648
        • Alijani M.R.
        • Cutler J.A.
        • DelValle C.J.
        Single-donor cold storage versus machine perfusion in cadaver kidney preservation.
        Transplantation. 1985; 40: 659-661
        • Halloran P.
        • Aprile M.
        A randomized prospective trial of cold storage versus pulsatile perfusion for cadaver kidney preservation.
        Transplantation. 1987; 43: 827-883
        • Polyak M.M.
        • Arrington B.O.
        • Stubenbord W.T.
        • et al.
        The influence of pulsatile preservation on renal transplantation in the 1990s.
        Transplantation. 2000; 69: 249-258
        • Heeman U.
        • Azuma H.
        • Tullius S.
        • et al.
        The contribution of reduced functional mass to chronic kidney allograft dysfunction in rats.
        Transplantation. 1994; 58: 1317-1322
        • Mackenzie H.S.
        • Tullius S.G.
        • Heeman U.W.
        • et al.
        Nephron supply is a major determinant of long-term renal allograft outcome in rats.
        J Clin Invest. 1994; 94: 2148-2152
        • Neugarten J.
        • Srinivas T.
        • Tellis V.
        • Silbiger S.
        • Greenstein S.
        The effect of donor gender on renal allograft survival.
        J Am Soc Nephrol. 1996; 7: 318-324
        • Brenner B.M.
        • Milford E.L.
        Nephron underdosing: a programmed cause of chronic renal allograft failure.
        Am J Kidney Dis. 1993; 21: 66-72
        • Papadimitriou J.C.
        • Coale R.
        • Farney A.
        • Schweitzer E.
        • Foster C.
        • Campos L.
        • Bartlett S.
        Biopsy of the marginal kidney donor: correlation of histology with outcome.
        Transplant Proc. 2004; 36: 742-744
        • Womer K.L.
        • Vella J.P.
        • Sayegh M.H.
        Chronic allograft dysfunction: Mechanisms and new approaches to therapy.
        Semin Nephrol. 2000; 20: 126-147
        • Nijboer W.N.
        • Schuurs T.A.
        • van der Hoeven J.A.
        • Leuvenink H.G.
        • van der Heide J.J.
        • van Goor H.
        • Ploeg R.J.
        Effects of brain death on stress and inflammatory response in the human donor kidney.
        Transplant Proc. 2005; 37: 367-369
        • Takada M.
        • Nadeau K.
        • Hancock W.
        • et al.
        Effects of explosive brain death on cytokine activation of peripheral organs in rat.
        Transplantation. 1998; 65: 1533-1542
        • Pratschke J.
        • Wilhelm M.J.
        • Kusaka M.
        • Beato F.
        • Milford E.L.
        • Hancock W.W.
        • Tilney N.L.
        Accelerated rejection of renal allografts from brain-dead donors.
        Ann Surg. 2000; 232: 263-271
        • Wilhelm M.J.
        • Pratschke J.
        • Beato F.
        • Taal M.
        • Kusaka M.
        • Hancock W.W.
        • Tilney N.L.
        Activation of the heart by donor brain death accelerates acute rejection after transplantation.
        Circulation. 2000; 102: 2426
        • Alonso A.
        • Fernandez-Rivera C.
        • Villaverde P.
        • Oliver J.
        • Cillero S.
        • Lorenzo D.
        • Valdes F.
        Renal transplantation from non-heart-beating donors: a single-center 10-year experience.
        Transplant Proc. 2005; 37: 3658-3660
        • Tullius S.
        • Heemann U.
        • Hancock W.
        • et al.
        Long term kidney isografts develop functional and morphological changes that mimic those of chronic allograft rejection.
        Ann Surg. 1994; 220: 432-435
        • Coulson M.T.
        • Jablonski P.
        • Howden B.O.
        • Thomson N.M.
        • Stein A.N.
        Beyond operational tolerance: effect of ischemic injury on development of chronic damage in renal grafts.
        Transplantation. 2005; 80: 353-361
        • Chandraker A.
        • Takada M.
        • Nadeau K.C.
        • et al.
        CD28-B7 blockade in organ dysfunction secondary to cold ischemia/reperfusion injury.
        Kidney Int. 1997; 52: 1678-1684
        • Land W.
        • Schneeberger H.
        • Schleibner S.
        • et al.
        The beneficial effect of human recombinant superoxide dismutase on acute and chronic rejection events in recipients of cadaveric renal transplants.
        Transplantation. 1994; 57: 211-217
        • Gueler F.
        • Gwinner W.
        • Schwarz A.
        • Haller H.
        Long-term effects of acute ischemia and reperfusion injury.
        Kidney Int. 2004; 66: 523
        • Kotsch K.
        • Francuski M.
        • Pascher A.
        • et al.
        Improved long-term graft survival after HO-1 induction in brain dead donors.
        Am J Transplant. 2006; 6: 477-486
        • Opelz G.
        • Wujciak T.
        • Ritz E.
        Association of chronic kidney graft failure with recipient blood pressure.
        Kidney Int. 1998; 53: 217-222
        • Mange K.C.
        • Cizman B.
        • Joffe M.
        • Feldman H.L.
        Arterial hypertension and renal allograft survival.
        JAMA. 2000; 283: 633-638
        • Kasiske B.L.
        • Anjum S.
        • Shah R.
        • et al.
        Hypertension after kidney transplantation.
        Am J Kidney Dis. 2004; 43: 1071-1081
        • Opelz G.
        • Döhler B.
        Improved long-term outcomes after renal transplantation associated with blood pressure control.
        Am J Transplant. 2005; 5: 2725
        • Mailloux L.U.
        • Levey A.S.
        Hypertension in patients with chronic renal disease.
        Am J Kidney Dis. 1998; 32: S120-S141
        • Lin J.
        • Valeri A.M.
        • Markowitz G.S.
        • et al.
        Angiotensin converting enzyme inhibition in chronic allograft nephropathy.
        Transplantation. 2002; 73: 783-788
        • Opelz G.
        • Zeier M.
        • Laux G.
        • et al.
        No improvement of patient or graft survival in transplant recipients treated with angiotensin-converting enzyme inhibitors or angiotensin II type 1 receptor blockers: a collaborative transplant study report.
        J Am Soc Nephrol. 2006; 17: 3257-3262
        • Wissing K.M.
        • Abramowicz D.
        • Broeders N.
        • et al.
        Hypercholestrolemia is associated with increased kidney graft loss caused by chronic rejection in male patients with previous acute rejection.
        Transplantation. 2000; 70: 464-472
        • Aakus S.
        • Dahl K.
        • Wideroe T.E.
        Cardiovascular morbidity and risk factors in renal transplant patients.
        Nephrol Dial Transplant. 1999; 14: 648-654
        • Mathis A.S.
        • Dave N.
        • Knipp G.T.
        • Friedman G.S.
        Drug-related dyslipidemia after renal transplantation.
        Am J Health Syst Pharm. 2004; 61: 565-587
        • Miller L.W.
        Cardiovascular toxicities of immunosuppressive agents.
        Am J Transplant. 2002; 2: 807-818
        • Murgia M.G.
        • Jordan S.
        • Kahan B.D.
        The side effect profile of sirolimus: a phase I study of quiescent cyclosporine-prednisone-treated renal transplant patients.
        Kidney Int. 1996; 49: 209-216
        • Blum C.B.
        Effects of sirolimus on lipids in renal allograft recipients: an analysis using Framingham risk model.
        Am J Transplant. 2002; 2: 551-559
        • Elloso M.M.
        • Azrolan N.
        • Sehgal S.N.
        • et al.
        Protective effect of the immunosuppressant sirolimus against aortic atherosclerosis in apo e-deficient mice.
        Am J Transplant. 2003; 3: 562-569
        • National Kidney Foundation
        Introduction, assessment of dyslipidemias, treating dyslipidemias, and research recommendations.
        Am J Kidney Dis. 2003; 41: S11-S91
        • Holdaas H.
        • Fellstrom B.
        • Jardine A.G.
        • et al.
        Effects of fluvastatin on cardiac events in renal transplant recipients: a multicentre, randomized, placebo-controlled trial.
        Lancet. 2003; 361: 2024-2031
        • Meier-Kriesche H.U.
        • Arndorfer J.A.
        • Kaplan B.
        The impact of body mass index on renal transplant outcomes: a significant independent risk factor for graft failure and patient death.
        Transplantation. 2002; 73: 70-74
        • Gore J.L.
        • Pham P.T.
        • Danovitch G.M.
        • Wilkinson A.H.
        • Rosenthal J.T.
        • Lipshutz G.S.
        • Singer J.S.
        Obesity and outcome following renal transplantation.
        Am J Transplant. 2006; 6: 357
        • Hirsch H.H.
        • Knowles W.
        • Dickenmann M.
        • et al.
        Prospective study of polyomavirus type BK replication and nephropathy in renal-transplant recipients.
        N Engl J Med. 2002; 347: 488
        • Brennan D.C.
        • Agha I.
        • Bohl D.L.
        • et al.
        Incidence of BK with tacrolimus versus cyclosporine and impact of preemptive immunosuppression reduction.
        Am J Transplant. 2005; 5: 582
        • Binet I.
        • Nickeleit V.
        • Hirsch H.H.
        • et al.
        Polyomavirus disease under new immunosuppressive drugs: a cause of renal graft dysfunction and graft loss.
        Transplantation. 1999; 67: 918
        • Trofe J.
        • Roy-Chaudhury P.
        • Gordon J.
        • et al.
        Early cessation/avoidance regimens are associated with lower incidence of polyomavirus nephropathy.
        Am J Transplantation. 2003; 3: 371
        • Dadhania D.
        • Muthukumar T.
        • Snopkowski C.
        • et al.
        Epidemiology of BK virus replication in renal allograft recipients and identification of corticosteroid maintenance therapy as an independent risk factor.
        Am J Transplantation. 2004; 4: S198
        • Mengel M.
        • Marwedel M.
        • Radermacher J.
        • et al.
        Incidence of polyomavirus-nephropathy in renal allografts: influence of modern immunosuppressive drugs.
        Nephrol Dial Transplant. 2003; 18: 1190
        • Hirsch H.H.
        • Brennan D.C.
        • Drachenberg C.B.
        Polyomavirus-associated nephropathy in renal transplantation: interdisciplinary analyses and recommendations.
        Transplantation. 2005; 79: 1277-1286
        • Inkinen K.
        • Soots A.
        • Krogerus L.
        • et al.
        Cytomegalovirus enhance expression of growth factors during the development of chronic allograft nephropathy in rats.
        Transplant Int. 2005; 18: 743
        • Weir M.R.
        • Ward M.T.
        • Blahut S.A.
        • et al.
        Long-term impact of discontinued or reduced calcineurin inhibitor in patients with chronic allograft nephropathy.
        Kidney Int. 2001; 59: 1567
        • Dudley C.R.K.
        • et al.
        • MMF “Creeping Creatinine” Study Group
        MMF substitution for CsA is an effective and safe treatment of chronic allograft dysfunction; results of a multi-center randomized controlled trial. American Transplant Congress, Washington2002
        • Flechner S.M.
        • Goldfarb D.
        • Modlin C.
        • et al.
        Kidney transplantation without calcineurin inhibitor drugs a prospective, randomized trial of sirolimus versus cyclosporine.
        Transplantation. 2002; 74: 1070
        • Larson T.S.
        • Dean P.G.
        • Stegall M.D.
        • et al.
        Complete avoidance of calcineurin inhibitors in renal transplantation: a randomized trial comparing sirolimus and tacrolimus.
        Am J Transplant. 2006; 6: 514-522
        • Mannon R.B.
        Therapeutic targets in the treatment of allograft fibrosis.
        Am J Transplant. 2006; 6: 867-875
        • Ling H.
        • Li X.
        • Jha S.
        • Wang W.
        • Karetskaya L.
        • Pratt B.
        • Ledbetter S.
        Therapeutic role of TGF-beta-neutralizing antibody in mouse cyclosporin A nephropathy: morphologic improvement associated with functional preservation.
        J Am Soc Nephrol. 2003; 14: 377-388
        • Khanna A.K.
        • Plummer M.S.
        • Hilton G.
        • Pieper G.M.
        • Ledbetter S.
        Anti–transforming growth factor antibody at low but not high doses limits cyclosporine-mediated nephrotoxicity without altering rat cardiac allograft survival.
        Circulation. 2004; 110: 3822-3829
        • Dong V.M.
        • Yuan X.
        • Coito A.J.
        • Waaga A.M.
        • Sayegh M.H.
        • Chandraker A.
        Mechanisms of targeting CD28 by a signaling monoclonal antibody in acute and chronic allograft rejection.
        Transplantation. 2002; 73: 1310-1317
        • Wekerle T.
        • Kurtz J.
        • Ito H.
        • Ronquillo J.V.
        • Dong V.
        • Zhao G.
        • Shaffer J.
        • Sayegh M.H.
        • Sykes M.
        Allogeneic bone marrow transplantation with co-stimulatory blockade induces macrochimerism and tolerance without cytoreductive host treatment.
        Nat Med. 2000; 6: 464-469
        • Kosuge H.
        • Suzuki J.
        • Gotoh R.
        • Koga N.
        • Ito H.
        • Isobe M.
        • Inobe M.
        • Uede T.
        Induction of immunologic tolerance to cardiac allograft by simultaneous blockade of inducible co-stimulator and cytotoxic T-lymphocyte antigen 4 pathway.
        Transplantation. 2003; 75: 1374-1379